ClinicalTrialsFinder
RecruitingPhase 2NCT06747858

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

Sponsor

Arcturus Therapeutics, Inc.

Enrollment

33 participants

Start Date

Dec 12, 2024

Study Type

INTERVENTIONAL

Conditions

Cystic FibrosisCFTR Gene Mutation

Summary

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called ARCT-032 for people with cftr gene mutation and cystic fibrosis. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALARCT-032

CFTR mRNA formulated in lipid nanoparticles

Locations(13)

University of Arizona

Tucson, Arizona, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

Children's National Hospital

Washington D.C., District of Columbia, United States

Joe DiMaggio Children's Hospital

Hollywood, Florida, United States

The Cystic Fibrosis Institute

Northfield, Illinois, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

UT Health San Antonio

San Antonio, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06747858

Related Trials

Role of Genetic Factors in the Development of Lung Disease

NCT000015322 locations

FEED-Cystic Fibrosis (FEED-CF)

NCT057667741 location

Natural History of Noncirrhotic Portal Hypertension

NCT024177401 location

Rare CFTR Mutation Cell Collection Protocol (RARE)

NCT031618081 location

Correction of Nonsense Mutations in Cystic Fibrosis

NCT036704728 locations